0000904454-20-000398.txt : 20200611 0000904454-20-000398.hdr.sgml : 20200611 20200611164922 ACCESSION NUMBER: 0000904454-20-000398 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200609 FILED AS OF DATE: 20200611 DATE AS OF CHANGE: 20200611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TREU JESSE I CENTRAL INDEX KEY: 0001013425 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 20957707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-06-09 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001013425 TREU JESSE I C/O DOMAIN ASSOCIATES, LLC 202 CARNEGIE CENTER, SUITE 104 PRINCETON NJ 08540 1 0 0 0 Stock Option (right to buy) 5.02 2020-06-09 4 A 0 26503 0 A 2021-06-09 2030-06-08 Common Stock 26503 26503 D Stock Option (right to buy) 5.02 2020-06-09 4 A 0 2465 0 A 2021-06-09 2030-06-08 Common Stock 2465 2465 D Stock Option (right to buy) 5.02 2020-06-09 4 A 0 2311 0 A 2021-06-09 2030-06-08 Common Stock 2311 2311 D The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Board of Directors through such vesting date. The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as the chairman of the Nominating and Corporate Governance Committee of the Board of Directors through such vesting date. The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Audit Committee of the Board of Directors through such vesting date. /s/ Lisa A. Kraeutler, Attorney-in-Fact 2020-06-11